Intracavitary administration of biological agents.
The intracavitary delivery of biological agents is based on sound pharmacologic, immunologic, and physiologic rationales. Results of early-stage clinical trials have confirmed both an advantage for exposure of the body cavity to the biologicals as compared with that of the systemic circulation following intracavitary drug delivery, as well as the suggestion of definite clinical utility. Trials that are in progress and those planned for the future will hopefully define optimal drug combinations, concentrations, and treatment schedules. Ultimately, randomized controlled trials will be required to define a role for such therapy as compared with standard therapeutic approaches to diseases principally confined to body cavities.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000008:administration & dosage*; D006023:Glycoproteins / Q000008:administration & dosage; D006801:Humans; D007274:Injections, Intraperitoneal; D007372:Interferons / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage; D014409:Tumor Necrosis Factor-alpha
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D001500:BCG Vaccine; D006023:Glycoproteins; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D007372:Interferons